Payment overview · 2025
General Payments
$638.58
32 reported records · 17 companies
Healthcare provider profile · identity verified
Kimberly A Smarsh, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARCO ISLAND, FL · NPI 1669050076
Verified facts
What the public records show
CMS Open Payments records show Kimberly A Smarsh, APRN received $638.58 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.64 | 13.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.15 | 10.7% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $63.10 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.15 | 8.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.11 | 7.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.44 | 7.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.13 | 7.1% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.63 | 5.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.34 | 4.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.36 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.35 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.18 | 3.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.99 | 3.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.86 | 3.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.47 | 3.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.07 | 3.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.61 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.58 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $63.10 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.34 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 85 |
| Losartan Potassium | Losartan Potassium | 197 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 73 |
| Alprazolam | Alprazolam | 177 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 153 | 59 |
| Lisinopril | Lisinopril | 147 | 48 |
| Simvastatin | Simvastatin | 126 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 31 |
| Omeprazole | Omeprazole | 98 | 40 |
| Ipratropium Bromide | Ipratropium Bromide | 89 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 78 |
| Montelukast Sodium | Montelukast Sodium | 81 | 31 |
| Alendronate Sodium | Alendronate Sodium | 80 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 23 |
| Sertraline Hcl | Sertraline Hcl | 66 | 24 |
| Trazodone Hcl | Trazodone Hcl | 64 | 28 |
| Gabapentin | Gabapentin | 60 | 26 |
| Metformin Hcl | Metformin Hcl | 60 | 21 |
| Meloxicam | Meloxicam | 58 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 23 |
| Famotidine | Famotidine | 57 | 27 |
| Methylprednisolone | Methylprednisolone | 57 | 54 |
| Synthroid | Levothyroxine Sodium | 56 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 43 |
| Potassium Chloride | Potassium Chloride | 50 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 46 |
| Baclofen | Baclofen | 44 | 22 |
| Valacyclovir | Valacyclovir Hcl | 44 | 19 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Estradiol | Estradiol | 42 | 25 |
| Jardiance | Empagliflozin | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Azithromycin | Azithromycin | 37 | 32 |
| Eliquis | Apixaban | 37 | 13 |
| Lorazepam | Lorazepam | 36 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 18 |
| Metformin Hcl Er | Metformin Hcl | 34 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 24 |
| Fluconazole | Fluconazole | 31 | 18 |
| Allopurinol | Allopurinol | 30 | 11 |
| Prednisone | Prednisone | 30 | 19 |
| Temazepam | Temazepam | 30 | suppressed |
| Furosemide | Furosemide | 29 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 11 |
| Celecoxib | Celecoxib | 24 | 11 |
| Clonazepam | Clonazepam | 24 | 11 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Diazepam | Diazepam | 22 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 17 |
| Nystatin | Nystatin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Mupirocin | Mupirocin | 16 | 14 |
| Naproxen | Naproxen | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Ramipril | Ramipril | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Vivelle-Dot | Estradiol | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $638.58 · 32 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, CONTRAVE, ENFLONSIA, EVENITY, Flector, GARDASIL 9, GATTEX, INSPIRE, JARDIANCE, Korlym, Licart, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tirosint, Tymlos, VOQUEZNA, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error